United Therapeutics developed Tyvaso (treprostinil) as a follow-on product to Remodulin. As an inhaled formulation of treprostinil, Tyvaso is better tolerated than continuously and subcutaneously administered Remodulin.
United Therapeutics has created a large market niche for its inhaled treprostinil formulation, Tyvaso, despite the drug being relegated to later lines of therapy and being unavailable outside the US. However, this niche is now under threat from newer, more convenient oral prostacyclins such as Uptravi (selexipag; Johnson & Johnson/Nippon Shinyaku), which further possesses a much stronger clinical dataset, as well as United Therapeutics’ own oral Orenitram (treprostinil). While these products have carved out a portion of Tyvaso’s market share, United Therapeutics may yet recoup losses through a first-to-market label expansion in pulmonary hypertension associated with lung disease (PH-LD). This will revive Tyvaso’s sales growth and dampen potential competition from LIQ861 (treprostinil; Liquidia Technologies) – a dry powder for inhalation currently in Phase III.
LIST OF FIGURES
10 Figure 1: Tyvaso for pulmonary hypertension – SWOT analysis
11 Figure 2: Datamonitor Healthcare’s drug assessment summary of Tyvaso for pulmonary hypertension
12 Figure 3: Datamonitor Healthcare’s drug assessment summary of Tyvaso for pulmonary hypertension
14 Figure 4: Tyvaso sales for pulmonary hypertension in the US, 2016–25
LIST OF TABLES
6 Table 1: Tyvaso drug profile
7 Table 2: Tyvaso pivotal trial data in pulmonary hypertension
9 Table 3: Tyvaso ongoing late-phase trials in pulmonary hypertension
15 Table 4: Tyvaso sales for pulmonary hypertension in the US ($m), 2016–25
Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is Suite 1, 3rd Floor, 11 - 12 St. James's Square, London, England, SW1Y 4LB. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.